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ABSTRACT
Cryopyrin-associated periodic syndrome (CAPS) is a hereditary autoinflammatory syndrome 
caused by mutations in NLRP3 (encoding cryopyrin), which presents with fever, fatigue 
and arthralgia. Thus far, however there have been no reports of CAPS in Korea. Herein, 
we report 3 cases of CAPS for the first time in Korea. The first case, a 28-year-old man 
with recurrent urticaria, arthralgia and fever induced by cold, all of which were observed 
in his father, showed elevated erythrocyte sedimentation rate and C-reactive protein. He 
exhibited a p.Gly303Asp variant of the NLPR3 gene. The second case, a 2-year-old girl who 
had recurrent urticaria, arthritis and oral and genital ulcers, was positive for HLA B51 and 
a p.Glu569Lys mutation in exon 3 of the NLRP3 gene. Administration of anakinra greatly 
improved her symptoms. The third case, a 4-year-old boy who presented with recurrent 
urticaria, arthralgia, and fever, exhibited a p.Val72Met mutation in exon 1 of the NLRP3 gene. 
Administration of tocilizumab improved all of his symptoms. This small case series suggests 
that clinicians consider CAPS and conduct genetic studies when arthralgia and fever are 
accompanied by urticaria in Korea.
Keywords: Cryopyrin-associated periodic syndromes; NLRP3 protein, human; NLR family, 
pyrin domain-containing 3 protein; urticaria; arthralgia
INTRODUCTION
Cryopyrin-associated periodic syndrome (CAPS) is a rare and hereditary autoinflammatory 
syndrome caused by mutations in NLRP3, which encodes cryopyrin.1 The clinical presentation 
of CAPS is characterized by periodic systemic inflammation including urticaria, fever and 
fatigue as well as signs of local inflammation that affects joints, skin, eyes, muscles and the 
central nervous system. The prevalence of CAPS is estimated at 1 to 3 in 1 million children 
and adults worldwide2; however, CAPS has not yet been reported in Korea. Establishing 
a diagnosis of CAPS is challenging because of its rarity; this results in significant delay in 
diagnosis and treatment. Here, we report 3 cases of CAPS, which comprise the first such 
reports in Korea, in order to raise awareness of CAPS among Korean clinicians.
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CASE REPORT
Case 1
A 28-year-old man with recurrent urticaria, arthralgia and fever induced by cold stimuli had 
received symptomatic treatment at other hospitals for 8 years. His father had exhibited the 
same symptoms since childhood, but did not know the source of these symptoms at the 
time of his death. This case 1 patient was diagnosed solely with cold urticaria; however, his 
arthralgia, fever and familial history were not explained by this initial diagnosis. Thus, he 
visited our hospital for a second opinion.
The urticaria developed repeatedly and was worsened by exposure to cold environments. It 
typically appeared and worsened in the winter; sometimes, it appeared in the summer upon 
exposure to air conditioning wind. Arthralgia, particularly at the knee joint, accompanied 
the presentation of urticaria (Fig. 1). Symptomatic treatment, including the use of anti-
inflammatory agents, had a minimal effect on the patient's symptoms. He showed elevated 
levels of C-reactive protein (5.2 mg/dL) and erythrocyte sedimentation rate (62 mm/h); other 
labs tests were within normal ranges. Antinuclear antibodies were positive, with a titer of 
1:80 and a cytoplastic pattern. The patient exhibited a p.Gly303Asp variant of the NLPR3 gene, 
which is known to cause familial cold autoinflammatory syndrome (FCAS) (Fig. 2).3,4 He was 
hesitant to undergo treatment with anti-interleukin (IL)-1 antibody because of the cost.
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Fig. 1. Urticaria on the trunk (A), hand (B) and leg with joint swelling (C) of the patient in case 1.
Case 2
A 2-year-old girl visited our hospital; she had had recurrent urticaria and arthritis 
(particularly at the knee joint) since birth. She was diagnosed with juvenile rheumatoid 
arthritis and underwent treatment accordingly; however, recurrent urticaria, fever and 
arthralgia continued. She exhibited an elevated level of C-reactive protein (9.63 mg/dL). 
New oral and genital ulcers developed, and a test for HLA B51 was positive. Therefore, she 
was diagnosed with Behçet's disease and was treated accordingly. However, her symptoms 
developed again and did not improve. After administration of anakinra, the patient's overall 
symptoms were much improved and her elevated levels of C-reactive protein returned 
to normal within 1 month (0.39 mg/dL). Then, genetic testing was conducted under the 
suspicion of CAPS; finally, a p.Glu569Lys mutation was found in exon 3 of the NLRP3 gene in 
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p.Val72Met (c.214G > A)
C
p.Glu569Lys (c.1705G > A)
B
Case 1
p.Gly303Asp (c.908G > A)
A
NLRP3 (NM_004895.4)
Case 3 NLRP3 (NM_004895.4)
Case 2 NLRP3 (NM_004895.4)
Fig. 2. Chromatogram of the NLPR3 gene mutations in the patients in cases 1 (A), 2 (B), and 3 (C).
this patient. Currently, her symptoms are well-controlled with intermittent steroid treatment 
combined with anakinra.
Case 3
A 4-year-old boy who complained of recurrent urticaria, fever and arthralgia, particularly at 
the knee joint, was admitted at another hospital, 2 years prior to this case. He was diagnosed 
with juvenile rheumatic arthritis and was treated with steroid and methotrexate. However, 
urticaria, fever and arthralgia continued. He was then admitted to our hospital for a second 
opinion. Genetic testing was conducted under suspicion of CAPS. Before genetic testing 
reveal the results, tocilizumab was administered to control juvenile rheumatic arthritis and 
CAPS, both, and all of his symptoms were improved; notably, elevated levels of CRP (10.1 mg/
dL) became normalized (0.03 mg/dL). Genetic testing shows finally, a p.Val72Met mutation 
was found in exon 1 of the NLRP3 gene in this patient. Presently, tocilizumab treatment is 
continued and the patient's overall symptoms remain well-controlled.
DISCUSSION
Herein, we report 3 cases of CAPS, which comprise the first such reports in Korea. CAPS is a 
hereditary autosomal-dominant autoinflammatory syndrome caused by mutations in NLRP3, 
which encodes cryopyrin.1 The clinical manifestation of CAPS is characterized by systemic 
inflammation, particularly involving fever and fatigue. Local signs affect several tissues such 
as joints, skin, eyes, muscles and the central nervous system. The most reliable diagnostic 
model for CAPS suggested by Kuemmerle-Deschner et al.5 is as follows: 1) more than 2 typical 
symptoms of CAPS (urticaria-like rash, cold-triggered episodes, sensorineural hearing loss, 
musculoskeletal symptoms, chronic aseptic meningitis and skeletal abnormalities); 2) raised 
inflammatory markers; and 3) genetic testing. All cases presented in this study met all the above 
criteria for CAPS. CAPS comprises 3 clinical types including FCAS, Muckle-Wells syndrome 
(MWS) and chronic infantile neurological, cutaneous, and articular (CINCA) syndrome. FCAS 
is characterized by cold-induced urticaria and fever. We suspect that the symptoms of the 
patient in case 1 and his father are concordant with a diagnosis of FCAS. MWS is characterized 
by systemic amyloidosis and hearing loss. CINCA, a neonatal-onset multisystem inflammatory 
disease, is characterized by central nervous system inflammation and bone deformities.6-8 All 3 
cases reported here exhibited no evidence of amyloidosis, hearing loss, nervous inflammation, 
or bone deformities. We suspect that these 3 cases of CAPS can be classified as FCAS; however, 
long-term follow-up is needed to confirm this diagnosis.
The patients in cases 2 and 3 were treated with monoclonal antibody (anti-IL-1 and anti-
IL-6 antibodies, respectively), and symptoms were greatly improved in both cases; however, 
the patient in case 1 could not be treated with monoclonal antibody because of the cost 
of treatment. CAPS is caused by a mutation in the NLRP3 gene, which encodes cryopyrin. 
Cryopyrin plays a central role in innate immunity, as it recognizes intracellular pathogens 
and some danger signals. In the cytoplasm, cryopyrin interacts with other proteins (caspase 
recruitment domain inhibitor [CARD] of NF-κB-activating ligands, apoptosis-associated 
speck-like protein containing a CARD and procaspase 1) to form the canonical inflammasome. 
This complex activates caspase-1 and eventually cleaves pro-IL-1 into its active form IL-1β.9 
This cytokine and downstream inflammatory mediators facilitate systemic and localized 
responses to infections and injuries. The purpose of treatment for patients with CAPS is to 
suppress continuous inflammation, prevent damage to organs and other parts of the body, 
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and overall, improve function. Traditionally, cold avoidance and anti-inflammatory drugs 
have been used as treatment; these approaches can reduce symptoms, but do not change the 
underlying pathogenesis of excessive IL-1 secretion. Blockage of IL-1 is the primary treatment 
approach, because IL-1 plays a central role in CAPS pathology. Currently, 3 IL-1 inhibitors, 
canakinumab, rilonacept and anakinra, are available; the safety and efficiency of these drugs 
have been reviewed and documented in many studies.10-12 However, IL-1 inhibitors have not yet 
been registered and approved in many countries. Another potent cytokine, IL-6, is generally 
considered to act downstream of IL-1β.13 Therefore, anti-IL-6 antibodies, such as tocilizumab, 
are considered for the treatment of CPAS patients.14 It is important to perform quick diagnosis 
and effective treatment, in order to prevent organ damage.
It is meaningful that this report describes the first CAPS patients in Korea, each of whom 
was confirmed to exhibit genetic mutations of NLPR3. The father of the patient in Case 1 also 
exhibited the same symptoms as a child, but did not know the exact etiology of the illness. 
CAPS itself is extremely rare, and diagnosis of CAPS in Korea may have been further delayed 
due to the lack of reporting in Korea. In Japan, the clinical characteristics of 19 patients 
were reviewed in 2012,15 and a study of the long-term safety and efficacy of canakinumab 
was conducted in 2017.16 Considering the number of patients in Japan nearby, we speculate 
that there are many cases of CAPS that have not yet been diagnosed in Korea. In previous 
reports of Korean patients, there was a case in which the CAPS was suspected due to 
repeated skin rash, arthritis and elevated CRP since childhood; however, the diagnosis of 
CAPS was not confirmed because a genetic study was not performed.17 Although urticaria 
and accompanying inflammatory symptoms from childhood are difficult to diagnose with 
certainty, it is necessary to consider family history and characteristic clinical patterns, in the 
context of the diagnosis of CAPS and during examination of suspected cases.
By reporting these cases, we hope to increase the awareness and ability to ensure early 
diagnosis of CAPS. We speculate that it will be helpful to have higher thresholds for clinical 
doubts regarding CAPS in patients with these symptoms, especially those with family history 
suggestive of CAPS.
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